BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
Keyword: Nab-paclitaxel
1
Nab-paclitaxel plus capecitabine as a first-line regimen for advanced biliary tract cancers: Feasible or not feasible?
2/26/2025 4:21:38 AM | Browse: 106 | Download: 429
2
Comparison of efficacy and safety of nab-paclitaxel and oxaliplatin + S-1 and standard S-1 and oxaliplatin chemotherapy regimens for treatment of gastric cancer
9/28/2024 4:34:22 AM | Browse: 148 | Download: 917
3
Nab-paclitaxel plus capecitabine as first-line treatment for advanced biliary tract cancers: An open-label, non-randomized, phase II clinical trial
8/9/2024 12:51:13 PM | Browse: 144 | Download: 1080
4
Meta-analysis of gemcitabine plus nab-paclitaxel combined with targeted agents in the treatment of metastatic pancreatic cancer
9/16/2022 11:52:44 AM | Browse: 527 | Download: 1269
5
Adjuvant nab-paclitaxel plus gemcitabine vs gemcitabine alone for resected pancreatic ductal adenocarcinoma: A single center experience in China
7/7/2020 3:43:52 AM | Browse: 992 | Download: 2570
6
FOLFIRINOX vs gemcitabine/nab-paclitaxel for treatment of metastatic pancreatic cancer: Single-center cohort study
2/15/2020 12:32:18 PM | Browse: 1151 | Download: 2603
7
Multiline treatment of advanced squamous cell carcinoma of lung: A case report and review of literature
7/26/2019 10:13:56 AM | Browse: 1127 | Download: 2451
8
Evolving treatment landscape for early and advanced pancreatic cancer
7/12/2017 6:47:21 AM | Browse: 1325 | Download: 2132
9
Pancreatic cancer: New hopes after first line treatment
9/12/2016 10:43:00 AM | Browse: 1358 | Download: 2019
10
Metastatic pancreatic cancer: Is there a light at the end of the tunnel?
4/27/2015 4:29:00 PM | Browse: 1275 | Download: 2476
11
Translational research in pancreatic ductal adenocarcinoma: current evidence and future concepts
8/20/2014 6:38:00 PM | Browse: 1564 | Download: 1540
Write to the Help Desk
© 1993-2026 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

California Corporate Number: 3537345